FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer

    NEXT STORY
    Global Human Vaccines Industry
    PREV STORY
    Excel Nuclear Oncology Center initiates the first Lu-177 DOTATOC PRRT clinical trial for the PUT-Neuroendocrine Tumors, in U.S.
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.

    author_avatar
    NASDAQ Market News

    Athenex, Inc. Announces Approval of Tax Incentives from State of New York for the Dunkirk Facility

    BUFFALO, N.Y., July 27, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Radius Health to Present Data on Abaloparatide at ASBMR 2019 Annual Meeting

    author_avatar
    NASDAQ Market News